Immunotherapy for breast cancer : a review of present and future perspectives
Authors: Dr. Labannya Das Puja
Institution: Sir Salimullah Medical College
Introduction
Immunotherapy is one of the most important advances in oncology. This review provides current developments of immunotherapy, implementation of challenges and upcoming perspectives.
Methods
It is a literature review that was extracted on articles and datas from clinicaltrials.gov, pubmed and google scholar on February 2025 in english language.
Results
In tripple negative breast cancer, combination of immunotherapy based on PD1/ PD-L1 immune check point inhibitors with chemotherapy was successful. Trials combining conventional therapy as well as other modalities like bispecific antibodies, CAR-T cells, cancer vaccines and oncolytic viruses in all breast cancer subtypes are also being investigated. Excellent result seen in absence of chemotherapy in patients with high tumor infiltrating lymphocytes and early stage triple negative breast cancer has led to neo adjuvant immunotherapy trials omitting chemotherapy.
Conclusion
The number of clinical trials have been increasing in all breast cancer subtypes. Future trials are in need to answer the question of de-escalating strategies for long term benefit.
